The BIHS disagrees with the recent BMJ editorial by Aronson & Ferner (Bmj 2020;369:m1313. doi: 10.1136/bmj.m1313 [published Online First: 2020/04/04]) who suggest that doctors may consider stopping treatment with ACE inhibitors and ARBs in well-controlled patients with mild (Stage 1) hypertension. A rebuttal article has been published today on BMJ Opinion. The unintended consequences of discontinuing effective treatments for hypertension, without a suitable replacement titrated against blood pressure measurements under direct medical supervision, could put patients at needlessly increased cardiovascular and possibly coronavirus risk. In addition, managing such titration currently, when primary care is prioritising acute illness over routine contacts (including blood pressure checks), makes the proposed strategy impractical and risks further diluting access to care.